Brief: UK's MHRA Authorises Nipocalimab To Treat Adults & Adolescents Aged 12 Years & Older With Generalised Myasthenia Gravis
09/06/2026 13:28
BRIEF-UK's MHRA Authorises Nipocalimab To Treat Adults & Adolescents Aged 12 Years & Older With Generalised Myasthenia Gravis June 9 (Reuters) - UK's MHRA:
UK'S MHRA: AUTHORISED MEDICINE NIPOCALIMAB (IMAAVY) TO TREAT ADULTS ADOLESCENTS AGED 12 YEARS OLDER WITH GENERALISED MYASTHENIA GRAVIS (GMG)
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Johnson & Johnson
See all newsFactbox: Global drugmakers invest billions to boost US presence
Press Digest: British Business - June 15
Brief: J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma
Brief: UK's MHRA Authorises Nipocalimab To Treat Adults & Adolescents Aged 12 Years & Older With Generalised Myasthenia Gravis
Factbox: Major deals involving US drugmakers and biotechs over the past decade